News

Clearmind Medicine has received Institutional Review Board (IRB) approval from Hadassah Medical Center in Jerusalem for its ongoing Phase...

Aptose Biosciences’ Phase 1/2 TUSCANY trial of tuspetinib (TUS) in combination with venetoclax and azacitidine (VEN/AZA) has cleared the...

Distalmotion has reached key enrollment milestones in two US pivotal trials for its DEXTER robotic surgery system: RAVEN for...

Arch Biopartners has dosed the first patient at Toronto General Hospital in its Phase 2 trial of LSALT peptide...

BioCardia is pursuing a two-pronged regulatory strategy in Q3/Q4 2025, seeking FDA approval for its Helix transendocardial delivery catheter...

Praxis Precision Medicines announced positive topline data from the Phase 2 RADIANT study of vormatrigine in focal onset seizures....

Cassava Sciences reports positive preclinical data for simufilam in a tuberous sclerosis complex (TSC) mouse model, specifically demonstrating anti-seizure...

Microbiotica has completed patient enrollment in its Phase 1b COMPOSER-1 trial of MB310, a live biotherapeutic product (LBP) for...

Allogene Therapeutics has discontinued the fludarabine, cyclophosphamide, and ALLO-647 (FCA) arm of its pivotal ALPHA3 study in first-line large...

Artelo Biosciences has received positive scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its...